Edition:
United Kingdom

Midatech Pharma PLC (MTP.OQ)

MTP.OQ on NASDAQ Stock Exchange Capital Market

0.75USD
24 Apr 2018
Change (% chg)

$0.00 (+0.00%)
Prev Close
$0.75
Open
$0.75
Day's High
$0.75
Day's Low
$0.75
Volume
130
Avg. Vol
18,260
52-wk High
$3.18
52-wk Low
$0.74

Chart for

About

Midatech Pharma PLC is an early-stage biopharmaceutical company that focuses on commercializing and developing products in oncology and other therapeutic areas. The Company's segments include Pipeline Research and Development, and Commercial. The Pipeline Research and Development segment seeks to develop products using the... (more)
No analyst recommendations are available for .

Overall

No Ratios Available.

Financials

  MTP.OQ Industry Sector
P/E (TTM): -- 178.44 32.31
EPS (TTM): -- -- --
ROI: -- -0.73 12.97
ROE: -- -2.77 14.84

BRIEF-Midatech Gets Orphan Drug Designation For Mtd119

* MIDATECH GETS ORPHAN DRUG DESIGNATION FOR MTD119 Source text for Eikon: Further company coverage: (Reuters.Briefs@thomsonreuters.com)

28 Feb 2018

BRIEF-Midatech Pharma Says Approval Of Investigational New Drug Application From US FDA To Conduct Study Of MTX110

* APPROVAL OF INVESTIGATIONAL NEW DRUG APPLICATION FROM US FDA TO CONDUCT A STUDY OF MTX110

16 Jan 2018

BRIEF-Midatech Pharma Enters Into Four-Year Senior Secured Loan Agreement With Midcap Financial Of Up To $15 Mln​

* MIDATECH PHARMA PLC - ‍HAS ENTERED INTO A FOUR-YEAR SENIOR SECURED LOAN AGREEMENT WITH MIDCAP FINANCIAL OF UP TO $15 MILLION​ Source text for Eikon: Further company coverage:

02 Jan 2018

BRIEF-Midatech Pharma U.S. Initiates Gelclair Phase IV Trial To Study Oral Mucositis In Stem Cell Transplant Patients

* MIDATECH PHARMA US INITIATES GELCLAIR® PHASE IV TRIAL TO STUDY ORAL MUCOSITIS IN STEM CELL TRANSPLANT PATIENTS

20 Dec 2017

Earnings vs. Estimates

No consensus analysis data available.